← Therapy pipeline
Investigational · Obesity development

Lenbelintide

AZD6234 · AstraZeneca

Selective amylin receptor agonist, including an adjunctive Phase 3 strategy.

amylin
Other study areas
Type 2 diabetes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorAstraZeneca
Targetsamylin
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Results availability

No numerical results shown

No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.

02 / How it works

Mechanism at a glance

GLP-1GLP-1—
GIPGIP—
GCGglucagon—
AMYamylinTargeted
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 3SELENE trials registered
Milestone → next

Latest: SELENE 1–3 Phase 3 obesity/overweight protocols registered by AstraZeneca.

Next: Enrollment and Phase 3 obesity outcomes.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies3 records

Phase 2 studies2 records

Phase 2

APRICUS

Weight management
Study: CompletedResults: No registry results posted yetStatus reviewed November 2026

Completed Phase 2 study of lenbelintide in overweight/obesity; no registry results posted.

Phase 2

ARAY

Weight management
Study: CompletedResults: No registry results posted yetStatus reviewed November 2026

Completed Phase 2 study of lenbelintide in overweight/obesity; no registry results posted.